Biological Assembly 1  

 3D View: Structure | Electron Density | Validation Report | Ligand Interaction

Global Symmetry: Cyclic - C2  (3D View)
Global Stoichiometry: Homo 2-mer - A2 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly Evidence: gel filtration

Macromolecule Content

• Total Structure Weight: 28.36 kDa 
• Atom Count: 2331 
• Modelled Residue Count: 239 
• Deposited Residue Count: 240 
• Unique protein chains: 1

6PNM

Human GSTO1-1 complexed with 2-chloro-N-(4-chloro-3-(morpholinosulfonyl)phenyl)acetamide

• DOI: 10.2210/pdb6PNM/pdb

• Classification: TRANSFERASE/TRANSFERASE INHIBITOR
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2019-07-02 Released: 2019-07-24 
• Deposition Author(s): Oakley, A.J.
• Funding Organization(s): National Health and Medical Research Council (NHMRC, Australia)

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.82 Å
• R-Value Free: 0.208 
• R-Value Work: 0.166 
• R-Value Observed: 0.168 

Literature

Development of Benzenesulfonamide Derivatives as Potent Glutathione Transferase Omega-1 Inhibitors.

Xie, Y., Tummala, P., Oakley, A.J., Deora, G.S., Nakano, Y., Rooke, M., Cuellar, M.E., Strasser, J.M., Dahlin, J.L., Walters, M.A., Casarotto, M.G., Board, P.G., Baell, J.B.

(2020) J Med Chem 63: 2894-2914

• PubMed: 32105470 
• DOI: 10.1021/acs.jmedchem.9b01391
• Primary Citation of Related Structures:  
  6PNM, 6PNN, 6PNO


• PubMed Abstract: 
  

Glutathione transferase omega-1 (GSTO1-1) is an enzyme whose function supports the activation of interleukin (IL)-1β and IL-18 that are implicated in a variety of inflammatory disease states for which small-molecule inhibitors are sought. The potent reactivity of the active-site cysteine has resulted in reported inhibitors that act by covalent labeling. In this study, structure-activity relationship (SAR) elaboration of the reported GSTO1-1 inhibitor C1-27 was undertaken. Compounds were evaluated for inhibitory activity toward purified recombinant GSTO1-1 and for indicators of target engagement in cell-based assays. As covalent inhibitors, the k _inact / K _I values of selected compounds were determined, as well as in vivo pharmacokinetics analysis. Cocrystal structures of key novel compounds in complex with GSTO1-1 were also solved. This study represents the first application of a biochemical assay for GSTO1-1 to determine k _inact / K _I values for tested inhibitors and the most extensive set of cell-based data for a GSTO1-1 inhibitor SAR series reported to date. Our research culminated in the discovery of 25 , which we propose as the preferred biochemical tool to interrogate cellular responses to GSTO1-1 inhibition.

---

Organizational Affiliation: 

ARC Centre for Fragment-Based Design, Monash University, Parkville, VIC 3052, Australia.

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Glutathione S-transferase omega-1	A	240	Homo sapiens	Mutation(s): 0  Gene Names: GSTO1, GSTTLP28 EC: 2.5.1.18 (PDB Primary Data), 1.8.5.1 (PDB Primary Data), 1.20.4.2 (PDB Primary Data)
UniProt & NIH Common Fund Data Resources
Find proteins for P78417 (Homo sapiens) Explore P78417  Go to UniProtKB:  P78417
PHAROS:  P78417 GTEx:  ENSG00000148834

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
XX0 (Subject of Investigation/LOI)	B [auth A]	2-chloro-N-{4-chloro-3-[(morpholin-4-yl)sulfonyl]phenyl}acetamide C12 H14 Cl2 N2 O4 S DGQBLXIZLVFBCI-UHFFFAOYSA-N
TLA	G [auth A]	L(+)-TARTARIC ACID C4 H6 O6 FEWJPZIEWOKRBE-JCYAYHJZSA-N
SO4	C [auth A], D [auth A], E [auth A], F [auth A]	SULFATE ION O4 S QAOWNCQODCNURD-UHFFFAOYSA-L

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.82 Å
• R-Value Free: 0.208 
• R-Value Work: 0.166 
• R-Value Observed: 0.168 
• Space Group: P 3₁ 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 57.25	α = 90
b = 57.25	β = 90
c = 139.85	γ = 120

Software Package:

Software Name	Purpose
REFMAC	refinement
MOSFLM	data reduction
Aimless	data scaling
PHASER	phasing

Structure Validation

Ligand Structure Quality Assessment  

Entry History & Funding Information

Deposition Data

• Deposited Date: 2019-07-02 
• Released Date: 2019-07-24 
Deposition Author(s): Oakley, A.J.

---

Funding Organization	Location	Grant Number
National Health and Medical Research Council (NHMRC, Australia)	Australia	APP1124673
National Health and Medical Research Council (NHMRC, Australia)	Australia	APP1156455

Revision History  

• Version 1.0: 2019-07-24
  Type: Initial release
  
• Version 1.1: 2020-01-08
  Changes: Author supporting evidence
• Version 1.2: 2020-03-11
  Changes: Database references
• Version 1.3: 2020-04-08
  Changes: Database references